Patents by Inventor Andrew C. Phillips

Andrew C. Phillips has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-EGFR ANTIBODY DRUG CONJUGATES
    Publication number: 20190343961
    Abstract: The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.
    Type: Application
    Filed: June 7, 2017
    Publication date: November 14, 2019
    Inventors: Erwin R. Boghaert, Milan Bruncko, Andrew S. Judd, Andrew C. Phillips, Andrew J. Souers
  • ANTI-EGFR ANTIBODY DRUG CONJUGATES
    Publication number: 20190153107
    Abstract: The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.
    Type: Application
    Filed: June 7, 2017
    Publication date: May 23, 2019
    Applicant: AbbVie Inc.
    Inventors: Erwin R. Boghaert, Milan Bruncko, George Doherty, Robin R. Frey, Andrew S. Judd, Andrew C. Phillips, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao
  • ANTI-EGFR ANTIBODY DRUG CONJUGATES
    Publication number: 20190153108
    Abstract: The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.
    Type: Application
    Filed: June 7, 2017
    Publication date: May 23, 2019
    Applicant: AbbVie Inc.
    Inventors: Erwin R. Boghaert, Milan Bruncko, Andrew S. Judd, Andrew C. Phillips, Andrew J. Souers
  • ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20190134216
    Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: October 8, 2018
    Publication date: May 9, 2019
    Inventors: Edward B. Reilly, Andrew C. Phillips, Lorenzo Benatuil, Chung-Ming Hsieh, Jennifer Perez
  • Durable silver-based mirror coating employing nickel oxide
    Publication number: 20190064398
    Abstract: A reflective optical coating has a thin film of silver as the primary reflecting material, a thin protective anti-oxidation layer of nickel oxide (NiO) deposited directly on top of the silver layer, and one or more thin transparent barrier layers deposited on top of the NiO, where each barrier layer is composed of a fluoride, a metal oxide, or a nitride. Optionally, a thin protective layer of NiO or Ni may be included, directly beneath the silver layer. Optionally, one or more thin barrier underlayer(s) may be included below the silver (and below the Ni or NiO protective layer, if present), where each of the barrier underlayers is a fluoride, a metal oxide, a metal nitride, or a bare metal.
    Type: Application
    Filed: August 24, 2018
    Publication date: February 28, 2019
    Inventors: Andrew C. Phillips, Nobuhiko Kobayashi, David M. Fryauf
  • Anti-EGFR antibodies and antibody drug conjugates
    Patent number: 10098968
    Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: October 16, 2018
    Assignee: Abbvie Inc.
    Inventors: Edward B. Reilly, Andrew C. Phillips, Lorenzo Benatuil, Chung-Ming Hsieh, Jennifer Perez
  • ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20180125999
    Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: November 9, 2017
    Publication date: May 10, 2018
    Inventors: EDWARD B. REILLY, ANDREW C. PHILLIPS, LORENZO BENATUIL, FRITZ G. BUCHANAN, JONATHAN A. MEULBROEK, CHUNG-MING HSIEH, JENNIFER PEREZ
  • ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20170355769
    Abstract: The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: June 7, 2017
    Publication date: December 14, 2017
    Inventors: Lorenzo Benatuil, Milan Bruncko, Debra Chao, Kamel Izeradjene, Andrew S. Judd, Andrew C. Phillips, Andrew J. Souers, Archana Thakur
  • Anti-EGFR antibodies and antibody drug conjugates
    Patent number: 9827330
    Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: November 28, 2017
    Assignee: Abbvie Inc.
    Inventors: Edward B. Reilly, Andrew C. Phillips, Lorenzo Benatuil, Chung-Ming Hsieh, Jennifer Perez
  • ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20170072065
    Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: November 11, 2016
    Publication date: March 16, 2017
    Inventors: Edward B. Reilly, Andrew C. Phillips, Lorenzo Benatuil, Fritz G. Buchanan, Jonathan A. Meulbroek, Chung-Ming Hsieh, Jennifer Perez
  • Method for optical coating of large scale substrates
    Publication number: 20160376705
    Abstract: A large substrate is optically coated in a reaction chamber that is formed by joining the substrate and a plate using a compliant seal, where the substrate forms one wall of the reaction chamber and the plate forms an opposite wall of the reaction chamber. The shape of the inside surface of the plate matches that of the inside surface of the substrate and they are spaced close together to minimize the volume of the reaction chamber. Atomic layer deposition is used to deposit one or more optical thin film layers to produce a coating on only the inside surface of the substrate. The outside surface is not coated.
    Type: Application
    Filed: June 13, 2016
    Publication date: December 29, 2016
    Inventors: Andrew C. Phillips, Nobuhiko Kobayashi
  • Anti-EGFR antibodies and antibody drug conjugates
    Patent number: 9493568
    Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: November 15, 2016
    Assignee: AbbVie Inc.
    Inventors: Edward B. Reilly, Andrew C. Phillips, Lorenzo Benatuil, Chung-Ming Hsieh, Jennifer Perez
  • ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20150337042
    Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: March 20, 2015
    Publication date: November 26, 2015
    Applicant: ABBVIE INC.
    Inventors: Edward B. Reilly, Andrew C. Phillips, Lorenzo Benatuil, Fritz G. Buchanan, Jonathan A. Meulbroek, Chung-Ming Hsieh, Jennifer Perez
  • SPECIFIC BINDING PROTEINS AND USES THEREOF
    Publication number: 20110313230
    Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
    Type: Application
    Filed: April 1, 2011
    Publication date: December 22, 2011
    Inventors: Terrance Grant Johns, Andrew Mark Scott, Gerd Ritter, Achim Jungbluth, Elizabeth Stockert, Stephen Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice, Anne Murray, George Mark, Lloyd J. Old, Edward B. Reilly, Andrew C. Phillips, Jonathan A. Meulbroek, Fritz G. Buchanan
  • SPECIFIC BINDING PROTEINS AND USES THEREOF
    Publication number: 20110293511
    Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
    Type: Application
    Filed: April 1, 2011
    Publication date: December 1, 2011
    Inventors: Terrance Grant Johns, Andrew Mark Scott, Gerd Ritter, Achim Jungbluth, Elizabeth Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice, Anne Murray, George Mark, Lloyd J. Old, Edward B. Reilly, Andrew C. Phillips, Jonathan A. Meulbroek, Fritz G. Buchanan, Stephen Stockert